N6-methyladenosine modification of FZR1 mRNA positively regulates antiviral innate immunity by targeting the MAVS-TRAF3/6 axis - PubMed
2 days ago
- #FZR1
- #m6A modification
- #antiviral immunity
- FZR1 plays a crucial role in antiviral innate immunity by enhancing type I interferon (IFN-I) production.
- N6-methyladenosine (m6A) modification of FZR1 mRNA increases its translation upon vesicular stomatitis virus infection.
- Upregulated FZR1 promotes MAVS aggregation by reducing its binding to a glycolytic enzyme.
- FZR1 facilitates TRAF3/6 autoubiquitination, activating IRF3 and NF-κB P65 to boost IFN-I and cytokine production.
- FZR1 deficiency or pharmacological inhibition weakens antiviral responses, increasing viral load in vitro and in vivo.
- The study reveals m6A modification of FZR1 as a key regulator of the MAVS-TRAF3/6 signaling axis in antiviral immunity.